Icon

Prevymis - (240, 480 mg ; Tablet)

Letermovir Merck
240, 480 mg ; Tablet
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
PREVYMIS is a CMV DNA terminase complex inhibitor indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
Yes
*** - *** **, ****
Prevymis Patent 1 Patent 2
***** ****** ******* **** **** **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** ****** *** \ ********* *** **, **** ******* ********* ******** *** ****** *** ****
  1. *** **, **** : *** **** ** ****** **** **** *** **** **** ****. ***** ** **** **** *** ****** ** ****.
  2. *** **, **** : ***** ****** *** ********* ********.
  3. *** **, **** : ***** *** ********* ********.
  4. *** **, **** : ***** ******** ***** ***** *** **** ** ******.
  5. *** **, **** : ***** **** ***** **** ************ ** ****** **. '*****.

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.